European journal of neurology · 2026
Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial.
СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gillmore Julian D, Adams David, Weiler Markus, Masri Ahmad, Obici Laura, Nåtman Jonatan, Kwoh T Jesse, Reicher Barry, Revkin James, Cruz Márcia Waddington, Gertz Morie, Chao Chi-Chao
Аннотация
BACKGROUND: This exploratory analysis of the NEURO-TTRansform Phase 3 trial evaluated the efficacy of eplontersen in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy by genetic variant.
METHODS: Changes from baseline in NEURO-TTRansform primary endpoints serum transthyretin (TTR) at Week 65, modified Neuropathy Impairment Score+7 (mNIS+7) composite score, and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at Week 66 were evaluated in patients with early-onset (aged < 50 years) and late-onset (aged ≥ 50 years) Val30Met (p.Val50Met) or non-Val30Met ATTRv amyloidosis with polyneuropathy. Secondary endpoints from NEURO-TTRansform were also evaluated by genetic variant.
RESULTS: In total, 144 patients with early-onset (n = 54) or late-onset (n = 31) Val30Met or non-Val30Met (n = 59), ATTRv amyloidosis with polyneuropathy were randomized to eplontersen. A further 60 patients from NEURO-TTR with early-onset (n = 16) or late-onset (n = 17) Val30Met or non-Val30Met (n = 27), served as a historical placebo group. The mean percentage difference (95% confidence interval) in serum TTR was -79.9 (-87.8, -72.0), -85.0 (-93.3, -76.6), and -70.6 (-77.7, -63.5) with eplontersen versus placebo in the early- and late-onset Val30Met, and non-Val30Met groups, respectively. Across subgroups, the change from baseline to Week 66 in mNIS+7 composite score was generally well maintained, and the Norfolk QoL-DN total score improved with eplontersen versus worsening with placebo. The Polyneuropathy Disability score was maintained in most patients. From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo.
CONCLUSIONS: Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT04136184, NCT01737398.
METHODS: Changes from baseline in NEURO-TTRansform primary endpoints serum transthyretin (TTR) at Week 65, modified Neuropathy Impairment Score+7 (mNIS+7) composite score, and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at Week 66 were evaluated in patients with early-onset (aged < 50 years) and late-onset (aged ≥ 50 years) Val30Met (p.Val50Met) or non-Val30Met ATTRv amyloidosis with polyneuropathy. Secondary endpoints from NEURO-TTRansform were also evaluated by genetic variant.
RESULTS: In total, 144 patients with early-onset (n = 54) or late-onset (n = 31) Val30Met or non-Val30Met (n = 59), ATTRv amyloidosis with polyneuropathy were randomized to eplontersen. A further 60 patients from NEURO-TTR with early-onset (n = 16) or late-onset (n = 17) Val30Met or non-Val30Met (n = 27), served as a historical placebo group. The mean percentage difference (95% confidence interval) in serum TTR was -79.9 (-87.8, -72.0), -85.0 (-93.3, -76.6), and -70.6 (-77.7, -63.5) with eplontersen versus placebo in the early- and late-onset Val30Met, and non-Val30Met groups, respectively. Across subgroups, the change from baseline to Week 66 in mNIS+7 composite score was generally well maintained, and the Norfolk QoL-DN total score improved with eplontersen versus worsening with placebo. The Polyneuropathy Disability score was maintained in most patients. From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo.
CONCLUSIONS: Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT04136184, NCT01737398.